Vivo Capital adds Aimmune Therapeutics Inc (AIMT) to its portfolio

Aimmune Therapeutics Inc (AIMT) : Vivo Capital added new position in Aimmune Therapeutics Inc during the most recent quarter end. The investment management firm now holds 763,009 shares of Aimmune Therapeutics Inc which is valued at $9,827,556 , the company said in a statement filed on Aug 15, 2016 with the SEC.Aimmune Therapeutics Inc makes up approximately 2.36% of Vivo Capital’s portfolio.

Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in AIMT in the latest quarter, The investment management firm added 115,700 additional shares and now holds a total of 604,098 shares of Aimmune Therapeutics Inc which is valued at $7,780,782. Sectoral Asset Management Inc sold out all of its stake in AIMT during the most recent quarter. The investment firm sold 982,133 shares of AIMT which is valued $12,649,873.Blackrock Advisors boosted its stake in AIMT in the latest quarter, The investment management firm added 4,722 additional shares and now holds a total of 8,799 shares of Aimmune Therapeutics Inc which is valued at $113,331.Teacher Retirement System Of Texas boosted its stake in AIMT in the latest quarter, The investment management firm added 1,102 additional shares and now holds a total of 2,658 shares of Aimmune Therapeutics Inc which is valued at $34,474.

Aimmune Therapeutics Inc formerly Allergen Research Corporation is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach including the development of proprietary candidates for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products defined treatment protocols and support services. Its lead product AR101 which has completed a Phase II study is designed to treat peanut allergy. The Company’s AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *